Hot on heels of a pos­i­tive PhI­II, Abl­ynx files $150M IPO; Shire sues Al­ler­gan over dry eye drug ri­val­ry

→ Af­ter watch­ing its Eu­ro­pean share price surge {$ABLX BB} yes­ter­day on pos­i­tive Phase III da­ta, Abl­ynx feels it’s per­fect tim­ing for an IPO on Nas­daq. The Bel­gian biotech is look­ing to raise around $150 mil­lion at a time a grow­ing num­ber of Eu­ro­pean biotechs have been find­ing a warm wel­come on the ex­change. The group is push­ing a new drug for ac­quired throm­bot­ic throm­bo­cy­topenic pur­pu­ra, or aTTP.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER